Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

Eli Lilly reported a 54% increase in Q3 2025 revenue, reaching $17.60 billion, driven primarily by strong sales of Mounjaro and Zepbound1.

For Q2 2025, worldwide revenue rose 38% year-over-year to $15.56 billion, with U.S. revenue at $10.81 billion and international revenue at $4.74 billion. Sales growth was primarily led by Zepbound and Mounjaro2 4 5.

Mounjaro revenue surged 68% to approximately $5.2 billion, while Zepbound revenue more than doubled to $3.38 billion year-over-year2.

Eli Lilly raised its full-year revenue forecast, with guidance now at $63.0–$63.5 billion for 2025, up from previous outlooks. Expected EPS is raised to a range of $21.80–$22.50 (non-GAAP EPS for Q2 was $7.02, beating expectations)1 2 4.

Q2 2025 net income jumped to $5.66 billion ($6.29 per share), up substantially from $2.97 billion ($3.28 per share) a year earlier2 3 4.

The company continues to advance its R&D pipeline, securing FDA and EU approvals for new treatments, launching promising data in oncology and cardiometabolic health, and expanding manufacturing capacity1 4.

Despite the strong financials, Eli Lilly's shares declined 13% after news that an experimental weight-loss pill produced lower weight loss than analysts anticipated2.

Recent business development includes completed acquisitions of SiteOne Therapeutics, Inc. and Verve Therapeutics, Inc., supporting growth and innovation4.